CERo End Period Cash Flow from 2010 to 2024

CEROW Stock   0.01  0  14.29%   
CERo Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to 92.03 in 2024. During the period from 2010 to 2024, CERo Therapeutics End Period Cash Flow regression line of quarterly data had mean square error of 112 T and geometric mean of  402,086. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
96.87
Current Value
92.03
Quarterly Volatility
10.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CERo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CERo Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 121.5 K, Interest Income of 121.5 K or Depreciation And Amortization of 2.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. CERo financial statements analysis is a perfect complement when working with CERo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of CERo Therapeutics Correlation against competitors.

Latest CERo Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of CERo Therapeutics Holdings over the last few years. It is CERo Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CERo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Pretty Stable
   End Period Cash Flow   
       Timeline  

CERo End Period Cash Flow Regression Statistics

Arithmetic Mean3,688,327
Geometric Mean402,086
Coefficient Of Variation288.61
Mean Deviation5,127,136
Median1,098,573
Standard Deviation10,644,787
Sample Variance113.3T
Range42.1M
R-Value0.29
Mean Square Error112T
R-Squared0.08
Significance0.30
Slope681,915
Total Sum of Squares1586.4T

CERo End Period Cash Flow History

2024 92.03
2023 96.87
202242.1 M

About CERo Therapeutics Financial Statements

CERo Therapeutics investors use historical fundamental indicators, such as CERo Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CERo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow 96.87  92.03 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CERo Stock Analysis

When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.